EUCTR2014-003386-22-GB进行中（未招募）1 期
A Single Centre, Open Label, Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Significant, Localised, Low to Intermediate Risk Prostate Cancer that is Associated with an MRI Lesion - Intraprostatic PRX302 injection to treat localised prostate cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Men aged =40 years and life expectancy of =10 years.
- •2.Serum prostate specific antigen (PSA) =15ng/mL.
- •3.In the planned treatment zone, histologically proven prostate cancer of maximum Gleason Score 7 (3+4 or 4+3)
- •In the presence of Gleason sum of 7, the maximum cancer core length must be 10mm or less
- •In the presence of Gleason sum of 7 there is no minimum cancer core length involvement
- •In the presence of Gleason patterns 3+3 the minimum cancer core length must exceed 3mm.
- •4.Radiological stage T1-T2 N0 Mx/M0 disease.
- •5.A visible lesion on mpMRI that is accessible to PRX302 transperineal injection. mpMRI to be obtained at the screening visit or within 3 months prior to dosing.
- •6.Transperineal prostate biopsy (template mapping and/or targeted) within 12 months prior to dosing, with a clinically significant lesion correlating with an mpMRI visible lesion.
- •7.Written informed consent by the patient for participation in the study.
- •8.Patient has an understanding of the English language sufficient to understand written and verbal information about the study and consent process.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1.Previous radiation therapy to the pelvis.
- •2.Androgen suppression or anti-androgen therapy within the 12 months prior to dosing, for prostate cancer.
- •3.Use of a 5-alpha reductase inhibitor within the 3 months prior to dosing.
- •4.Evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging.
- •5.Presence of Gleason score >7 and/or maximum cancer core length involvement of >3mm outside of the planned treatment zone.
- •6.A tumour within the prostate not visible on mpMRI.
- •7.Inability to tolerate a transrectal ultrasound (TRUS).
- •8.Known allergy to latex or gadolinium (Gd).
- •9.Prior rectal surgery preventing insertion of the TRUS probe.
- •10.Previous electroporation, radiofrequency ablation, high-intensity focused ultrasound (HIFU), cryosurgery, thermal or microwave therapy to treat cancer of the prostate.
- •11.Transurethral resection of the prostate (TURP) for symptomatic lower urinary tract symptoms within the 6 months prior to dosing.
- •12.Not fit for major surgery as assessed by a Consultant Anaesthetist.
- •13.Unable to have pelvic MRI scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant, etc. likely to contribute significant artefact to images).
- •14.Presence of metal implants/stents in the urethra or any other non-MRI compatible metal objects.
- •15.Renal impairment with an estimated glomerular filtration rate (GFR) of <35mL/min (unable to tolerate Gd dynamic contrast enhanced MRI).
- •16.Use of ANY of the following medications:
- •Anticoagulants (e.g., Coumadin, heparin) or platelet inhibitors (e.g., aspirin, nonsteroidal anti-inflammatory drugs [NSAIDs], clopidogrel [e.g., Plavix®]) within 5 days prior to dosing or anticipated for use any time within the first 3 days after dosing or per local guidelines.
- •Androgen deprivation therapy will not be permitted during study duration unless the development of metastases (rare) occurred during study follow-up. 5-alpha reductase inhibitors will not be permitted during the study until the post-treatment biopsies have been taken.
- •17.Any condition that may confound the assessment of safety and tolerability, such as current symptomatic prostatitis; acute or chronic or symptomatic genitourinary infection; or urinary retention requiring catheterisation within 12 months prior to dosing or elevated International Normalized Ratio (INR) > 1.5 at the time of dosing.
- •18.Any acute or chronic medical condition that, in the opinion of the Investigator, increases the risk to the patient or the likelihood that the patient will be unable to complete the 30-week study.
- •19.Unable or unwilling to comply with the requirements of the protocol.
- •20.Participation in any investigational study within 30 days prior to dosing.
研究者
相似试验
进行中（未招募）
不适用
A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formulation administered subcutaneously as two doses of 120 mg in patients with advanced prostate cancerEUCTR2005-002100-42-LTArdana Bioscience Ltd8
进行中（未招募）
不适用
A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formulation administered subcutaneously as two doses of 120 mg (given as 2 injections of 60 mg on Day 1 and repeated on Day 2) in patients with advanced prostate cancerADVANCED PROSTATE CANCEREUCTR2005-005742-39-LTArdana Bioscience Ltd8
招募中
1 期
A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patientsCTIS2023-505241-10-00Medibiofarma S.L.10
招募中
1 期
A phase IIa, open label, Single-centre study to assess the initial antifibrotic efficacy, safety, tolerability, pharmacokinetic and pharmacodynamic profile of MBF-118 in Crohn’s disease patients with stenosis.Crohn’s diseaseMedDRA version: 20.0Level: PTClassification code: 10011401Term: Crohn's disease Class: 100000004856CTIS2022-501464-18-00Medibiofarma S.L.10
招募中
2 期
An open label, study to evaluate the safety of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation.Acute Graft Versus Host DiseaseHematopoietic Stem Cell TransplantationCancer - Other cancer typesBlood - Haematological diseasesACTRN12619000623190Kalytera Therapeutics Israel Ltd36